first-in-human dose-escalation study of TX45 in healthy volunteers
Latest Information Update: 31 Dec 2024
At a glance
Most Recent Events
- 18 Nov 2024 Results (n=55) assessing the tolerability and safety, immunogenicity, pharmacokinetic (PK) and pharmacodynamicof TX45 in healthy volunteers after single doses, presented at the American Heart Association Scientific Sessions 2024.
- 20 Jun 2024 According to a Tectonic Therapeutic media release, AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic.
- 30 Jan 2024 According to the AVROBIO media release, Following completion of the ongoing dose escalation safety and PK/PD studies in healthy volunteers, development of TX45 is planned to focus on an area of very high unmet need,